. Forest plot for the secondary analysis comparing use of DPP-4 inhibitors with use of sulfonylureas on the incidence of pancreatic cancer Abbreviations: DPP-4, dipeptidyl peptidase-4; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis.
Supplemental Figure 2.
Forest plot for the secondary analysis comparing use of GLP-1 analogues with use of sulfonylureas on the incidence of pancreatic cancer Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period.
Supplemental Figure 10 . Forest plot for the secondary analysis assessing the association between cumulative duration of DPP-4 inhibitor use of ≥2 years and pancreatic cancer* Abbreviations: CI, confidence interval; DPP-4, dipeptidyl peptidase-4; HR, hazard ratio; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to participating sites generating stable estimates (Ontario, Quebec, MarketScan). Figure 13 . Forest plot for the secondary analysis assessing the association between cumulative durations of GLP-1 analogue use of < 1 year and pancreatic cancer* Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period. Figure 14 . Forest plot for the secondary analysis assessing the association between cumulative durations of GLP-1 analogue use of 1-1.9 years and pancreatic cancer* Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period. Figure 15 . Forest plot for the secondary analysis assessing the association between cumulative durations of GLP-1 analogue use of ≥2 years and pancreatic cancer* Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period. Figure 16 . Forest plot for the secondary analysis assessing the association between initiation of GLP-1 analogues between 1 and 1.9 years before index date and pancreatic cancer* Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period.
Supplemental

Supplemental Figure 17 . Forest plot for the secondary analysis assessing the association between initiation of GLP-1 analogues ≥2 years before index date and pancreatic cancer* Abbreviations: GLP-1, glucagon-like peptide-1; CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Note: This analysis was limited to the United Kingdom Clinical Practice Research Datalink and the United States MarketScan, the two sites where GLP-1 analogues were available during the study period. Figure 20 . Forest plot for the sensitivity analysis using a stricter exposure definition for incretin-based drugs (at least 4 prescriptions within a 12-month window)* Abbreviations: CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States. *The reference category is use of sulfonylureas. The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. Figure 23 . Forest plot for the sensitivity analysis comparing use of incretin-based drugs with use of sulfonylureas adjusted for a reduced set of covariates* Abbreviations: CI, confidence interval; HR, hazard ratio; UK, United Kingdom; US, United States The size of the boxes is proportional to the weight of a given participating site in the random-effects meta-analysis. *Adjusted for the Deyo version of the Charlson comorbidity index and history of acute or chronic pancreatitis. * When the total across participating sites was less than 6, data were suppressed (denoted by an S) due to privacy restrictions. When summing data across sites, we assigned a value of 3 to small cells (≤5). As such, the sum of count data may differ from the presented total. † Data from the UK Clinical Practice Research Datalink. ‡ Non-mutually exclusive categories.
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